References
- Heininger K, (2000) A unifying hypothesis of Alzheimer’s disease. IV. Causation and sequence of events. Rev Neurosci. 11: Spec No: 213-328
- Yin, F., Boveris, A., and Cadenas, E. (2014). Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid. Redox Signal. 20, 353–371.
- Lourenço CF, Ledo A, Dias C, Barbosa RM, Laranjinha J. Neurovascular and neurometabolic derailment in aging and Alzheimer’s disease. (2015) Frontiers in Aging Neuroscience. 7:103.
- de la Monte SM, Wands JR (2008) Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2: 1101-1113.
- Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, et al. (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J Alzheimers Dis 7: 63-80.
- Sato N, Morishita R. (2015) The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. Frontiers in Aging Neuroscience. 7:199.
- Zlokovic BV. (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 57:178–201.
- Hoyer S. (1998) Is sporadic Alzheimer disease the brain type of non–insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm. 105(4–5):415–422.
- Iwangoff P, Armbruster R, Enz A, Meier-Ruge W. (1980) Glycolytic enzymes from human autoptic brain cortex: normal aged and demented cases. Mech Ageing Dev. 14(1-2):203–9.
- Sims NR, et.al. (1980) Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer’s disease. Lancet. 1(8164):333–6.
- Tong M, Deochand C, Didsbury J, de la Monte SM (2016) T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer’s Disease. J Alzheimers Dis 51, 123-138.
- Tong M, Dominguez C, Didsbury J, de la Monte SM (2016) Targeting Alzheimer’s Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. J Alzheimers Dis Parkinsonism 6: 238. doi: 10.4172/2161- 0460.1000238.
- http://www.ddw-online.com/therapeutics/p213493-targeting-diminished-cerebral-glucose-metabolism-for-alzheimer%E2%80%99s-disease-summer-13.html
- Chen Z, Zhong C. (2013) Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Progress in Neurobiology 108:21-43.
- Iwashita A. et.al. (2007) Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J Pharmacol. Exp. Ther. 320:1087-1096.
- Bright, JJ, et al. (2008) PPAR regulation of inflammatory signaling in CNS diseases, PPAR Research. Article ID 658520, doi:10.1155/2008/658520.
- de la Monte SM, et.al. (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimers Dis. 10(1):89–109.
- Fortress AM, et al. (2013) Canonical Wnt Signaling is Necessary for Object Recognition Memory Consolidation. Journal of Neuroscience. 33 (31): 12619-26.
- Inestosa NC and Toledo EM. (2008) The role of Wnt signaling in neuronal dysfunction in Alzheimer’s Disease. Mol Neurodegener. 3:3-9.
- Scholtysek, C, et.al. (2013) PPARβ/δ governs Wnt signaling and bone turnover, Nature Medicine. 19:608-13.
- Kummer, MP and Heneka MT. (2008) PPARs in Alzheimer’s Disease, PPAR Research. Article ID 403896;
- Kalinin, S. et.al. (2009) A PPAR delta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer’s disease. Curr. Alzheimer Res. 6(5):431-7.
- Barroso E, Santos A,, Porquet D, Del Valle J, Michalik L, Wahli W, Vázquez-Carrera M. (2012) Peroxisome Proliferator-Activated Receptor Beta/Delta-Deficient Mice Show Increased Inflammation And Tau Phosphorylation In Cortex. FENS Abstract. 6:p044.28.
- Dunn SE, Bhat R, Straus DS, Sobel RA, Axtell R, et al. (20100 Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med. 207:1599–1608.
- Tokutake T, et al. (2012) Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway J Biol Chem. 287(42):35222-33).
- Grady CL, Haxby JV, Schlageter NL, Berg G, Rapoport SI (1986) Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology 36: 1390-1392.
- Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32: 486-510.
- Mosconi L, McHugh PF (2011) FDG- and amyloid-PET in Alzheimer’s disease: Is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging 55: 250-264.
- Brown AM, Sheu RK, Mohs R, Haroutunian V, Blass JP (2001) Correlation of the clinical severity of Alzheimer’s disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci 16: 41-48.
- Arnaiz E, et al. (2001) Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 12(4):851-5.
- Landau SM, Harvey D, Madison CM, et al. (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 32(7):1207-18.
- Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry. 159:738–745.
- Engler H, Forsberg A, Almkvist O, et al. (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain. 129:2856–2866.
- Dickey, A.S., Pineda, V.V., Tsunemi, T., Liu, P.P., Miranda, H.C., Gilmore-Hall, S.K., Lomas, N., Sampat, K.R., Buttgereit, A., Torres, M.J. et al. (2016) PPAR-delta is repressed in Huntington’s disease, is required for normal neuronal function and can be targeted therapeutically. Nat Med, 22, 37-45.